MeMed
Tel Aviv, Israel· Est.
MeMed delivers FDA‑cleared, 15‑minute host‑immune response tests that differentiate bacterial and viral infections, supporting better clinical decisions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
MeMed delivers FDA‑cleared, 15‑minute host‑immune response tests that differentiate bacterial and viral infections, supporting better clinical decisions.
Infectious DiseasesInflammatory Disorders
Technology Platform
A multiplex immunoassay combined with machine‑learning algorithms that decodes host‑immune biomarkers into rapid, actionable diagnostic read‑outs.
Opportunities
Expansion of MeMed Severity into U.S.
emergency departments and entry into European and Asian markets could dramatically increase addressable volume and reimbursement streams.
Risk Factors
Regulatory delays, payer reimbursement uncertainty, and competition from larger diagnostics firms could limit market penetration.
Competitive Landscape
MeMed competes with pathogen‑based rapid tests and inflammatory markers (e.g., BioMérieux, Quidel) but differentiates through its host‑immune response approach and 15‑minute point‑of‑care turnaround.